Drug-grafted DNA as a novel chemogene for targeted combinatorial cancer therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapeutics

Background:

• Combinatorial therapy using chemotherapy and gene agents offers synergistic antitumor effects.
• Efficient co-delivery of these agents is a significant challenge due to differing pharmacodynamics.
• Developing novel drug delivery systems is crucial for advancing cancer treatment.

Purpose of the Study:

• To develop a novel chemogene for targeted co-delivery of chemotherapy and gene therapy agents.
• To overcome the limitations of traditional combinatorial cancer therapies.
• To create a precise and efficient platform for synergistic antitumor treatment.

Main Methods:

• Site-specific grafting of camptothecins (CPTs) onto a DNA backbone.
• Incorporation of an AS1411 aptamer for cancer cell targeting.
• Inclusion of a BCL-2 antisense sequence for gene knockdown.
• Utilizing a disulfide linkage for responsive drug release.
• In vitro and in vivo evaluations of the chemogene's efficacy.

Main Results:

• The developed DNA-drug conjugate demonstrated precise composition and controllable drug loading.
• Targeted co-delivery of chemo and gene agents to the tumor site was achieved.
• Efficient BCL-2 gene knockdown and significant induction of cancer cell apoptosis were observed.
• Enhanced antitumor efficacy was demonstrated in both in vitro and in vivo models.

Conclusions:

• The novel CPT-bearing chemogene offers a simple and effective strategy for combinatorial cancer therapy.
• This approach facilitates targeted co-delivery, gene knockdown, and apoptosis induction.
• The facile synthesis and precise structure suggest potential for clinical translation in antitumor treatment.